The roles of amyloid-β and tau in the degenerative process of Alzheimer’s disease (AD) remain uncertain. [18F]AV-45 and [18F]AV-1451 PET quantify amyloid-β and tau pathology, respectively, while diffusion tractography enables detection of their microstructural consequences.
Objective:
Examine the impact of amyloid-β and tau pathology on the structural connectome and cognition, in mild cognitive impairment (MCI) and AD.
Methods:
Combined [18F]AV-45 and [18F]AV-1451 PET, diffusion tractography, and cognitive assessment in 28 controls, 32 MCI, and 26 AD patients.
Results:
Hippocampal connectivity was reduced to the thalami, right lateral orbitofrontal, and right amygdala in MCI; alongside the insula, posterior cingulate, right entorhinal, and numerous cortical regions in AD (all p < 0.05). Hippocampal strength inversely correlated with [18F]AV-1451 SUVr in MCI (r = –0.55, p = 0.049) and AD (r = –0.57, p = 0.046), while reductions in hippocampal connectivity to ipsilateral brain regions correlated with increased [18F]AV-45 SUVr in those same regions in MCI (r = –0.33, p = 0.003) and AD (r = –0.31, p = 0.006). Cognitive scores correlated with connectivity of the right temporal pole in MCI (r = –0.60, p = 0.035) and left hippocampus in AD (r = 0.69, p = 0.024). Clinical Dementia Rating Scale scores correlated with [18F]AV-1451 SUVr in multiple areas reflecting Braak stages I-IV, including the right (r = 0.65, p = 0.004) entorhinal cortex in MCI; and Braak stages III-VI, including the right (r = 0.062, p = 0.009) parahippocampal gyrus in AD.
Conclusion:
Reductions in hippocampal connectivity predominate in the AD connectome, correlating with hippocampal tau in MCI and AD, and with amyloid-β in the target regions of those connections. Cognitive scores correlate with microstructural changes and reflect the accumulation of tau pathology.
Levy-LahadE, WascoW, PoorkajP, RomanoDM, OshimaJ, PettingellWH, YuCE, JondroPD, SchmidtSD, WangK, et al. (1995) Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science269, 973–977.
10.
RogaevEI, SherringtonR, RogaevaEA, LevesqueG, IkedaM, LiangY, ChiH, LinC, HolmanK, TsudaT, MarL, SorbiS, NacmiasB, PiacentiniS, AmaducciL, ChumakovI, CohenD, LannfeltL, FraserPE, RommensJM, St George-HyslopPH (1995) Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature376, 775–778.
11.
KarranE, MerckenM, De StrooperB (2011) The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov10, 698–712.
12.
ChitiF, DobsonCM (2017) Protein misfolding, amyloid formation, and human disease: A summary of progress over the last decade. Annu Rev Biochem86, 27–68.
13.
HardyJ, De StrooperB (2017) Alzheimer’s disease: Where next for anti-amyloid therapies?Brain140, 853–855.
14.
AizensteinHJ, NebesRD, SaxtonJA, PriceJC, MathisCA, TsopelasND, ZiolkoSK, JamesJA, SnitzBE, HouckPR, BiW, CohenAD, LoprestiBJ, DeKoskyST, HalliganEM, KlunkWE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol65, 1509–1517.
15.
KatzmanR, TerryR, DeTeresaR, BrownT, DaviesP, FuldP, RenbingX, PeckA (1988) Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol23, 138–144.
16.
PanzaF, LozuponeM, LogroscinoG, ImbimboBP (2019) A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat Rev Neurol15, 73–88.
NelsonPT, JichaGA, SchmittFA, LiuH, DavisDG, MendiondoMS, AbnerEL, MarkesberyWR (2007) Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: Neuritic plaques and neurofibrillary tangles “do count” when staging disease severity. J Neuropathol Exp Neurol66, 1136–1146.
19.
PickettEK, HenstridgeCM, AllisonE, PitstickR, PoolerA, WegmannS, CarlsonG, HymanBT, Spires-JonesTL (2017) Spread of tau down neural circuits precedes synapse and neuronal loss in the rTgTauEC mouse model of early Alzheimer’s disease. Synapse71, e21965.
20.
NakamuraK, GreenwoodA, BinderL, BigioEH, DenialS, NicholsonL, ZhouXZ, LuKP (2012) Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer’s disease. Cell149, 232–244.
21.
KondoA, ShahpasandK, MannixR, QiuJ, MoncasterJ, ChenCH, YaoY, LinYM, DriverJA, SunY, WeiS, LuoML, AlbayramO, HuangP, RotenbergA, RyoA, GoldsteinLE, Pascual-LeoneA, McKeeAC, MeehanW, ZhouXZ, LuKP (2015) Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature523, 431–436.
MishraS, GordonBA, SuY, ChristensenJ, FriedrichsenK, JacksonK, HornbeckR, BalotaDA, CairnsNJ, MorrisJC, AncesBM, BenzingerTLS (2017) AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. Neuroimage161, 171–178.
24.
ChienDT, BahriS, SzardeningsAK, WalshJC, MuF, SuMY, ShankleWR, ElizarovA, KolbHC (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis34, 457–468.
25.
SmithR, PuschmannA, SchollM, OhlssonT, van SwietenJ, HonerM, EnglundE, HanssonO (2016) 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain139, 2372–2379.
26.
SchultzSA, GordonBA, MishraS, SuY, PerrinRJ, CairnsNJ, MorrisJC, AncesBM, BenzingerTLS (2018) Widespread distribution of tauopathy in preclinical Alzheimer’s disease. Neurobiol Aging72, 177–185.
27.
JohnsonKA, SperlingRA, GidicsinCM, CarmasinJS, MayeJE, ColemanRE, ReimanEM, SabbaghMN, SadowskyCH, FleisherAS, Murali DoraiswamyP, CarpenterAP, ClarkCM, JoshiAD, LuM, GrundmanM, MintunMA, PontecorvoMJ, SkovronskyDM, AV45-A11 study group (2013) Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement9, S72–83.
28.
SchwarzAJ, YuP, MillerBB, ShcherbininS, DicksonJ, NavitskyM, JoshiAD, DevousMDSr., MintunMS (2016) Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain139, 1539–1550.
SchöllM, SchonhautD, LockhartS, VogelJW, BakerS, SchwimmerH, OssenkoppeleR, RabinoviciGD, JagustWJ (2015) In vivo braak staging using 18F-AV1451 Tau PET imaging. Alzheimers Dement11, P4.
ChoiSR, SchneiderJA, BennettDA, BeachTG, BedellBJ, ZehntnerSP, KrautkramerMJ, KungHF, SkovronskyDM, HeftiF, ClarkCM (2012) Correlation of amyloid PET ligand florbetapir F 18 binding with Abeta aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord26, 8–16.
33.
SchöllM, LockhartSN, SchonhautDR, O’NeilJP, JanabiM, OssenkoppeleR, BakerSL, VogelJW, FariaJ, SchwimmerHD, RabinoviciGD, JagustWJ (2016) PET imaging of tau deposition in the aging human brain. Neuron89, 971–982.
34.
MitchellAJ, Shiri-FeshkiM (2009) Rate of progression of mild cognitive impairment to dementia–meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand119, 252–265.
35.
TucholkaA, Grau-RiveraO, FalconC, RamiL, Sanchez-ValleR, LladoA, GispertJD, MolinuevoJL, Alzheimer’s Disease Neuroimaging Initiative (2018) Structural connectivity alterations along the alzheimer’s disease continuum: Reproducibility across two independent samples and correlation with cerebrospinal fluid amyloid-beta and tau. J Alzheimers Dis61, 1575–1587.
36.
YeC, MoriS, ChanP, MaT (2019) Connectome-wide network analysis of white matter connectivity in Alzheimer’s disease. Neuroimage Clin22, 101690.
StrainJF, SmithRX, BeaumontH, RoeCM, GordonBA, MishraS, AdeyemoB, ChristensenJJ, SuY, MorrisJC, BenzingerTLS, AncesBM (2018) Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. Neurology91, e313–e318.
47.
KantarciK, MurrayME, SchwarzCG, ReidRI, PrzybelskiSA, LesnickT, ZukSM, RamanMR, SenjemML, GunterJL, BoeveBF, KnopmanDS, ParisiJE, PetersenRC, JackCR, DicksonDW (2017) White-matter integrity on DTI and the pathologic staging of Alzheimer’s disease. Neurobiol Aging56, 172–179.
IaccarinoL, TammewarG, AyaktaN, BakerSL, BejaninA, BoxerAL, Gorno-TempiniML, JanabiM, KramerJH, LazarisA, LockhartSN, MillerBL, MillerZA, O’NeilJP, OssenkoppeleR, RosenHJ, SchonhautDR, JagustWJ, RabinoviciGD (2018) Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer’s disease. Neuroimage Clin17, 452–464.
51.
OssenkoppeleR, SchonhautDR, BakerSL, O’NeilJP, JanabiM, GhoshPM, SantosM, MillerZA, BettcherBM, Gorno-TempiniML, MillerBL, JagustWJ, RabinoviciGD (2015) Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol77, 338–342.
52.
O’BryantSE, WaringSC, CullumCM, HallJ, LacritzL, MassmanPJ, LupoPJ, ReischJS, DoodyR, Texas Alzheimer’s Research Consortium (2008) Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: A Texas Alzheimer’s research consortium study. Arch Neurol65, 1091–1095.
53.
MoradiE, HallikainenI, HanninenT, TohkaJ, Alzheimer’s Disease Neuroimaging Initiative (2017) Rey’s Auditory Verbal Learning Test scores can be predicted from whole brain MRI in Alzheimer’s disease. Neuroimage Clin13, 415–427.
54.
Estevez-GonzalezA, KulisevskyJ, BoltesA, OterminP, Garcia-SanchezC (2003) Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer’s disease: Comparison with mild cognitive impairment and normal aging. Int J Geriatr Psychiatry18, 1021–1028.
55.
SchmidtM (1996) Rey auditory verbal learning test: A handbook, Western Psychological Services Los Angeles, CA.
56.
PfefferRI, KurosakiTT, HarrahCH, ChanceJM, FilosS (1982) Measurement of functional activities in older adults in the community. J Gerontol37, 323–329.
57.
TengE, BeckerBW, WooE, KnopmanDS, CummingsJL, LuPH (2010) Utility of the Functional Activities Questionnaire for distinguishing mild cognitive impairment from very mild Alzheimer disease. Alzheimer Dis Assoc Disord24, 348–353.
58.
LiuC-C, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–118.
59.
Zavaliangos-PetropuluA, NirTM, ThomopoulosSI, ReidRI, BernsteinMA, BorowskiB, JackCRJr., WeinerMW, JahanshadN, ThompsonPM (2019) Diffusion MRI indices and their relation to cognitive impairment in brain aging: The updated multi-protocol approach in ADNI3. Front Neuroinform13, 2.
TournierJD, SmithR, RaffeltD, TabbaraR, DhollanderT, PietschM, ChristiaensD, JeurissenB, YehCH, ConnellyA (2019) MRtrix3: A fast, flexible and open software framework for medical image processing and visualisation. Neuroimage202, 116137.
63.
JenkinsonM, SmithS (2001) Global optimisation method for robust affine registration of brain images. Med Image Anal5, 143–156.
64.
JenkinsonM, BannisterP, BradyM, SmithS (2002) Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage17, 825–841.
BraakH, BraakE (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging18, 351–357.
68.
Serrano-PozoA, FroschMP, MasliahE, HymanBT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med1, a006189–a006189.
69.
ThalDR, RübU, OrantesM, BraakH (2002) Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology58, 1791–1800.
70.
RoussetOG, MaY, EvansAC (1998) Correction for partial volume effects in PET: Principle and validation. J Nucl Med39, 904–911.
71.
BakerSL, MaassA, JagustWJ (2017) Considerations and code for partial volume correcting [(18)F]-AV-1451 tau PET data. Data Brief15, 648–657.
72.
MaassA, LandauS, BakerSL, HorngA, LockhartSN, La JoieR, RabinoviciGD, JagustWJ, Alzheimer’s Disease Neuroimaging Initiative (2017) Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer’s disease. Neuroimage157, 448–463.
73.
DiedrichsenJ, MaderwaldS, KuperM, ThurlingM, RabeK, GizewskiER, LaddME, TimmannD (2011) Imaging the deep cerebellar nuclei: A probabilistic atlas and normalization procedure. Neuroimage54, 1786–1794.
74.
PennyW, FristonK, AshburnerJ, KiebelS, E., NicholsT (2007) Statistical Parametric Mapping.
75.
JoshiAD, PontecorvoMJ, ClarkCM, CarpenterAP, JenningsDL, SadowskyCH, AdlerLP, KovnatKD, SeibylJP, AroraA, SahaK, BurnsJD, LowreyMJ, MintunMA, SkovronskyDM, FlorbetapirF18 Study Investigators (2012) Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer’s disease and cognitively normal subjects. J Nucl Med53, 378–384.
GuoT, KormanD, La JoieR, ShawLM, TrojanowskiJQ, JagustWJ, LandauSM (2020) Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer’s disease. Alzheimers Res Ther12, 97.
VeraartJ, NovikovDS, ChristiaensD, Ades-AronB, SijbersJ, FieremansE (2016) Denoising of diffusion MRI using random matrix theory. Neuroimage142, 394–406.
81.
AnderssonJLR, SotiropoulosSN (2016) An integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging. Neuroimage125, 1063–1078.
82.
VeraartJ, FieremansE, NovikovDS (2016) Diffusion MRI noise mapping using random matrix theory. Magn Reson Med76, 1582–1593.
83.
SmithSM, JenkinsonM, WoolrichMW, BeckmannCF, BehrensTE, Johansen-BergH, BannisterPR, De LucaM, DrobnjakI, FlitneyDE, NiazyRK, SaundersJ, VickersJ, ZhangY, De StefanoN, BradyJM, MatthewsPM (2004) Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage23Suppl 1, S208–219.
84.
TournierJD, CalamanteF, ConnellyA (2007) Robust determination of the fibre orientation distribution in diffusion MRI: Non-negativity constrained super-resolved spherical deconvolution. Neuroimage35, 1459–1472.
85.
TournierJD, CalamanteF, GadianDG, ConnellyA (2004) Direct estimation of the fiber orientation density function from diffusion-weighted MRI data using spherical deconvolution. Neuroimage23, 1176–1185.
86.
SmithRE, TournierJD, CalamanteF, ConnellyA (2015) The effects of SIFT on the reproducibility and biological accuracy of the structural connectome. Neuroimage104, 253–265.
87.
KrzywinskiM, ScheinJ, BirolI, ConnorsJ, GascoyneR, HorsmanD, JonesSJ, MarraMA (2009) Circos: An information aesthetic for comparative genomics. Genome Res19, 1639–1645.
88.
RubinovM, SpornsO (2010) Complex network measures of brain connectivity: Uses and interpretations. Neuroimage52, 1059–1069.
89.
PapezJW (1995) A proposed mechanism of emotion. 1937. J Neuropsychiatry Clin Neurosci7, 103–112.
90.
AggletonJP, PralusA, NelsonAJ, HornbergerM (2016) Thalamic pathology and memory loss in early Alzheimer’s disease: Moving the focus from the medial temporal lobe to Papez circuit. Brain139, 1877–1890.
91.
RollsET (2015) Limbic systems for emotion and for memory, but no single limbic system. Cortex62, 119–157.
92.
NakanoI (1998) The limbic system: An outline and brief history of its concept. Neuropathology18, 211–214.
93.
LandauSM, BreaultC, JoshiAD, PontecorvoM, MathisCA, JagustWJ, MintunMA (2013) Amyloid-β imaging with Pittsburgh Compound B and florbetapir: Comparing radiotracers and quantification methods. J Nucl Med54, 70–77.
94.
NicholsT, HayasakaS (2003) Controlling the familywise error rate in functional neuroimaging: A comparative review. Stat Methods Med Res12, 419–446.
95.
GenoveseCR, LazarNA, NicholsT (2002) Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage15, 870–878.
96.
BenjaminiY, HochbergY (1995) Controlling The False Discovery Rate - a practical and powerful approach to multiple testing. J R Stat Soc Series B57, 289–300.
97.
MotulskyHJ, BrownRE (2006) Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics7, 123.
98.
MallerJJ, WeltonT, MiddioneM, CallaghanFM, RosenfeldJV, GrieveSM (2019) Revealing the hippocampal connectome through super-resolution 1150-direction diffusion MRI. Sci Rep9, 2418.
99.
AguzziA, RajendranL (2009) The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron64, 783–790.
100.
WalkerLC, DiamondMI, DuffKE, HymanBT (2013) Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol70, 304.
Spires-JonesTL, HymanBT (2014) The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. Neuron82, 756–771.
103.
ZareiM, PatenaudeB, DamoiseauxJ, MorgeseC, SmithS, MatthewsPM, BarkhofF, RomboutsSA, Sanz-ArigitaE, JenkinsonM (2010) Combining shape and connectivity analysis: An MRI study of thalamic degeneration in Alzheimer’s disease. Neuroimage49, 1–8.
104.
BishnoiRJ, SuryaS, McCallWV (2017) Structural integrity of white matter tracts in papez circuit during the course of Alzheimer’s disease. Alzheimers Dement13, P1379.
105.
GoodroeSC, StarnesJ, BrownTI (2018) The complex nature of hippocampal-striatal interactions in spatial navigation. Front Hum Neurosci12, 250.
106.
de JongLW, FerrariniL, van der GrondJ, MillesJR, ReiberJH, WestendorpRG, BollenEL, MiddelkoopHA, van BuchemMA (2011) Shape abnormalities of the striatum in Alzheimer’s disease. J Alzheimers Dis23, 49–59.
107.
PievaniM, BocchettaM, BoccardiM, CavedoE, BonettiM, ThompsonPM, FrisoniGB (2013) Striatal morphology in early-onset and late-onset Alzheimer’s disease: A preliminary study. Neurobiol Aging34, 1728–1739.
108.
ChoH, KimJH, KimC, YeBS, KimHJ, YoonCW, NohY, KimGH, KimYJ, KimJH, KimCH, KangSJ, ChinJ, KimST, LeeKH, NaDL, SeongJK, SeoSW (2014) Shape changes of the basal ganglia and thalamus in Alzheimer’s disease: A three-year longitudinal study. J Alzheimers Dis40, 285–295.
109.
PackardMG, KnowltonBJ (2002) Learning and memory functions of the basal ganglia. Annu Rev Neurosci25, 563–593.
110.
SchoenbergMR, CliftonWE, SeverRW, ValeFL (2018) Neuropsychology outcomes following trephine epilepsy surgery: The inferior temporal gyrus approach for amygdalohippocampectomy in medically refractory mesial temporal lobe epilepsy. Neurosurgery82, 833–841.
111.
BiesbroekJM, Van ZandvoortMJE, KappelleLJ, SchooL, KuijfHJ, VelthuisBK, BiesselsGJ, PostmaA (2015) Distinct anatomical correlates of discriminability and criterion setting in verbal recognition memory revealed by lesion-symptom mapping. Hum Brain Mapp36, 1292–1303.
112.
SudoFK, De SouzaAS, DrummondC, AssuncaoN, TeldeschiA, OliveiraN, RodriguesF, Santiago-BravoG, CalilV, LimaG, ErthalP, BernardesG, MonteiroM, Tovar-MollF, MattosP (2019) Inter-method and anatomical correlates of episodic memory tests in the Alzheimer’s Disease spectrum. PLoS One14, e0223731.
NakamuraK, KubotaK (1996) The primate temporal pole: Its putative role in object recognition and memory. Behav Brain Res77, 53–77.
115.
MajdanA, SziklasV, Jones-GotmanM (1996) Performance of healthy subjects and patients with resection from the anterior temporal lobe on matched tests of verbal and visuoperceptual learning. J Clin Exp Neuropsychol18, 416–430.
116.
GourN, RanjevaJP, CeccaldiM, Confort-GounyS, BarbeauE, SoulierE, GuyeM, DidicM, FelicianO (2011) Basal functional connectivity within the anterior temporal network is associated with performance on declarative memory tasks. Neuroimage58, 687–697.
117.
VisserM, JefferiesE, Lambon RalphMA (2010) Semantic processing in the anterior temporal lobes: A meta-analysis of the functional neuroimaging literature. J Cogn Neurosci22, 1083–1094.
118.
KennedyRE, CutterGR, WangG, SchneiderLS (2015) Using baseline cognitive severity for enriching Alzheimer’s disease clinical trials: How does Mini-Mental State Examination predict rate of change?Alzheimers Dement (N Y)1, 46–52.
119.
PontecorvoMJ, DevousMD, KennedyI, NavitskyM, LuM, GalanteN, SallowayS, DoraiswamyPM, SouthekalS, AroraAK, McGeehanA, LimNC, XiongH, TruocchioSP, JoshiAD, ShcherbininS, TeskeB, FleisherAS, MintunMA (2019) A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia. Brain142, 1723–1735.
120.
LeeCM, JacobsHIL, MarquiéM, BeckerJA, AndreaNV, JinDS, SchultzAP, FroschMP, Gómez-IslaT, SperlingRA, JohnsonKA (2018) 18F-flortaucipir binding in choroid plexus: Related to race and hippocampus signal. J Alzheimers Dis62, 1691–1702.
121.
WangL, BenzingerTL, SuY, ChristensenJ, FriedrichsenK, AldeaP, McConathyJ, CairnsNJ, FaganAM, MorrisJC, AncesBM (2016) Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between β-amyloid and tauopathy. JAMA Neurol73, 1070.
122.
LoweVJ, CurranG, FangP, LiesingerAM, JosephsKA, ParisiJE, KantarciK, BoeveBF, PandeyMK, BruinsmaT, KnopmanDS, JonesDT, PetrucelliL, CookCN, Graff-RadfordNR, DicksonDW, PetersenRC, JackCR, MurrayME (2016) An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun4, 58.
